Nazan Bayram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nazan Bayram has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Meral Uyar
Department of Chest Diseases, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
9 shared publications Ayten Filiz
Department of Respiratory Medicine, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
8 shared publicationsOsman Elbek
Department of Pulmonary Medicine, Adnan Menderes University
7 shared publicationsMeral Uyar
Sanko University Dept. of Pulmonary Diseases, Gaziantep, Turkey
4 shared publications- Oner Dikensoy
Koç University Medicine Faculty
4 shared publications Erhan Ekinci
3 shared publications
Latest Publications
- Open Access
- 20 February 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (5) , 2687-2696
The differences between the subtypes of obstructive sleep apnea among different provinces in Turkey: a multicenter study
Purpose: Our aim in this study is to investigate the significance and implications of different clinical subtypes of patients with obstructive sleep apnea syndrome (OSAS) in three different sleep centers from varied provinces. Methods: Between January 2023 and November 2024, 330 patients from three sleep centers (Adana, Gaziantep, and Istanbul) were retrospectively examined for age, gender, body mass index (BMI), polysomnography parameters, sleep stages, arousals, oxygen parameters, heart rates, apnea-hypopnea indexes (AHI) and snoring. Results: OSAS patients of Gaziantep were fat and severe OSAS patients who slept lightly but efficiently at lower oxygen levels with longer durations. They fell into Rapid Eye Movement (REM) sleep quickly. The number of hypopneas is high. OSAS patients of Adana sleep deeply, frequently wake after sleep onset, and snore less. The number of obstructive apnea is high. OSAS patients of Istanbul sleep efficiently but snore a lot. REM oxygen saturation, oxygen desaturation index (ODI) levels, and the average heart rate were high in Istanbul. The number of central and mixed apneas is high. Conclusions: Sleep patterns and oxygen measurements varied among clinical subtypes of patients with OSAS, as well as among provinces. Understanding regional or subtype-specific OSAS could alter practice because treatment can be planned according to the severity of OSAS.
- 20 February 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (5) , 2687-2696
Open AccessThe differences between the subtypes of obstructive sleep apnea among different provinces in Turkey: a multicenter study
Purpose: Our aim in this study is to investigate the significance and implications of different clinical subtypes of patients with obstructive sleep apnea syndrome (OSAS) in three different sleep centers from varied provinces. Methods: Between January 2023 and November 2024, 330 patients from three sleep centers (Adana, Gaziantep, and Istanbul) were retrospectively examined for age, gender, body mass index (BMI), polysomnography parameters, sleep stages, arousals, oxygen parameters, heart rates, apnea-hypopnea indexes (AHI) and snoring. Results: OSAS patients of Gaziantep were fat and severe OSAS patients who slept lightly but efficiently at lower oxygen levels with longer durations. They fell into Rapid Eye Movement (REM) sleep quickly. The number of hypopneas is high. OSAS patients of Adana sleep deeply, frequently wake after sleep onset, and snore less. The number of obstructive apnea is high. OSAS patients of Istanbul sleep efficiently but snore a lot. REM oxygen saturation, oxygen desaturation index (ODI) levels, and the average heart rate were high in Istanbul. The number of central and mixed apneas is high. Conclusions: Sleep patterns and oxygen measurements varied among clinical subtypes of patients with OSAS, as well as among provinces. Understanding regional or subtype-specific OSAS could alter practice because treatment can be planned according to the severity of OSAS.
- 28 March 2024
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 19 (1) , 1-7
Impact of Adaptive Servo-Ventilation in Heart Failure Patients
Background: Sleep related breathing disorders (SRBD) as obstructive apnea, central apnea and Cheyne-Stokes respiration (CSR) can be seen in patients with chronic heart failure. SRBD can influence prognosis of heart failure. Objective: To reveal sleep related breathing disorders in patients with heart failure and to display the effects of adaptive servo-ventilation (ASV) as a new therapy modality. Materials and Methods: In this prospective study, 32 patients with heart failure were included. One night polysomnography (PSG) was done. Results: According to the results of PSG, SRBD ratio was 96,7%. Continuous positive airway pressure (CPAP) and ASV titrations were offered to all patients with apnea-hypopnea index (AHI) > 5. Demographics and clinical properties, symptoms, PSG findings, presence of Cheyne-Stokes respiration (CSR), echocardiography results were recorded. Before and after ASV titration, pulmonary function tests, walking tests were performed, concentrations of transferrin and pro-BNP were determined. In the groups according to the AHI, severe OSAS in 18 of 30 patients, 4 moderate OSAS, 5 mild OSAS and 2 central sleep apnea (CSA). PSG and CPAP, ASV titrations done in 7 male and 1 female patients that obstructive apnea, central apnea, AHI, arousal and SpO2 min values had significant improvements (p=0,001 p=0,016 p=0,001 p=0,015 p=0,008 respectively). We determined all CSRs were eliminated with ASV. After ASV titration pro-BNP, walking distance and FVC values changed significantly (p=0,036 p=0,018 p=0,018 respectively). Conclusion: In the result, we determined cheyne-stokes respiration and central apneas persisted with CPAP but eliminated with one-night ASV application. ASV also decreased pro-BNP and increased FVC and walking distance values significantly.
- 28 March 2024
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 19 (1) , 1-7
Impact of Adaptive Servo-Ventilation in Heart Failure Patients
Background: Sleep related breathing disorders (SRBD) as obstructive apnea, central apnea and Cheyne-Stokes respiration (CSR) can be seen in patients with chronic heart failure. SRBD can influence prognosis of heart failure. Objective: To reveal sleep related breathing disorders in patients with heart failure and to display the effects of adaptive servo-ventilation (ASV) as a new therapy modality. Materials and Methods: In this prospective study, 32 patients with heart failure were included. One night polysomnography (PSG) was done. Results: According to the results of PSG, SRBD ratio was 96,7%. Continuous positive airway pressure (CPAP) and ASV titrations were offered to all patients with apnea-hypopnea index (AHI) > 5. Demographics and clinical properties, symptoms, PSG findings, presence of Cheyne-Stokes respiration (CSR), echocardiography results were recorded. Before and after ASV titration, pulmonary function tests, walking tests were performed, concentrations of transferrin and pro-BNP were determined. In the groups according to the AHI, severe OSAS in 18 of 30 patients, 4 moderate OSAS, 5 mild OSAS and 2 central sleep apnea (CSA). PSG and CPAP, ASV titrations done in 7 male and 1 female patients that obstructive apnea, central apnea, AHI, arousal and SpO2 min values had significant improvements (p=0,001 p=0,016 p=0,001 p=0,015 p=0,008 respectively). We determined all CSRs were eliminated with ASV. After ASV titration pro-BNP, walking distance and FVC values changed significantly (p=0,036 p=0,018 p=0,018 respectively). Conclusion: In the result, we determined cheyne-stokes respiration and central apneas persisted with CPAP but eliminated with one-night ASV application. ASV also decreased pro-BNP and increased FVC and walking distance values significantly.
- Open Access
- 7 November 2023
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
- Vol. 29 (4) , 698-705
Factors Affecting Treatment Compliance of Patients With COPD During the COVID-19 Pandemic
Objective: This study aimed to investigate the effects of difficulties experienced in the follow-up and treatment during the Coronavirus 2019 pandemic (COVID-19p), which included COVID-19 phobia and depression, on treatment compliance in patients with Chronic Obstructive Pulmonary Disease (COPD). Methods: This study included 123 patients with COPD. The COVID-19 Phobia Scale (C19P-S), Beck Depression Inventory (BDI), and Medication Adherence Report Scale (MARS) were used to assess the patients. Results: The mean age of patients with COPD was 64.56 ± 9.31 years. It was determined that our patients did not maintain regular outpatient follow-up mostly because of the fear of COVID-19 transmission (78.8%). Overall, 24% of our patients showed treatment noncompliance. A statistically significant relationship was found between COPD stages B and D and treatment compliance (p=0.01). Patients with frequent emergency department admissions (p = 0.01) and those with high BDI (p = 0.01) and C19P-S (p = 0.02) scores during the pandemic were found to have reduced treatment compliance. Conclusion: Patients with COPD with COVID-19 phobia, and depression had reduced treatment compliance. İt is necessary to be aware of these conditions and to plan appropriate interventions.
- 7 November 2023
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
- Vol. 29 (4) , 698-705
Open AccessFactors Affecting Treatment Compliance of Patients With COPD During the COVID-19 Pandemic
Objective: This study aimed to investigate the effects of difficulties experienced in the follow-up and treatment during the Coronavirus 2019 pandemic (COVID-19p), which included COVID-19 phobia and depression, on treatment compliance in patients with Chronic Obstructive Pulmonary Disease (COPD). Methods: This study included 123 patients with COPD. The COVID-19 Phobia Scale (C19P-S), Beck Depression Inventory (BDI), and Medication Adherence Report Scale (MARS) were used to assess the patients. Results: The mean age of patients with COPD was 64.56 ± 9.31 years. It was determined that our patients did not maintain regular outpatient follow-up mostly because of the fear of COVID-19 transmission (78.8%). Overall, 24% of our patients showed treatment noncompliance. A statistically significant relationship was found between COPD stages B and D and treatment compliance (p=0.01). Patients with frequent emergency department admissions (p = 0.01) and those with high BDI (p = 0.01) and C19P-S (p = 0.02) scores during the pandemic were found to have reduced treatment compliance. Conclusion: Patients with COPD with COVID-19 phobia, and depression had reduced treatment compliance. İt is necessary to be aware of these conditions and to plan appropriate interventions.
- 23 May 2022
- Published by Galenos Yayinevi in Journal of Turkish Sleep Medicine
- Vol. 9 (2) , 147-152
Anxiety Levels, Sleep Quality and Follow-up of Obstructive Sleep Apnoea Patients During the COVID-19 Pandemic
- 23 May 2022
- Published by Galenos Yayinevi in Journal of Turkish Sleep Medicine
- Vol. 9 (2) , 147-152
Anxiety Levels, Sleep Quality and Follow-up of Obstructive Sleep Apnoea Patients During the COVID-19 Pandemic
- 15 September 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 52 (suppl 62) , PA2773
Comparison of endobronchial ultrasound-guided transbronchial needle aspiration and positron emission tomography standard uptake values in mediastinal or hilar lymph node evaluation in benign, granulomatous and malignant disease
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and positron emission tomography (PET) standard uptake values (SUV) are useful methods for evaluating mediastinal lymph node pathology. The aim this study was to compare EBUS TBNA and PET suv results in benign, granulomatous and malignant disease. The files of 151 patients who had FDG-PET scanning and underwent EBUS-TBNA between 2015-2017 were reviewed. The diagnoses were confirmed by needle aspiration cytology, histopathology and clinical follow-up. Malignant diseases included lung cancers, metastasis and lymphomas. Granulomatous diseases were mainly sarcoidosis and tuberculosis. Benign group comprised mainly of patients suspected with relapse of malignancy in whom it was disproved or no specific diagnosis was reached during follow-up. The patients included 101 males and 50 females with mean age 58.64±12.46 (26-86). A total of 356 stations were sampled with an average of 2.36 stations per case. Malignancy was observed in 100 lymph nodes with a mean SUV of 10.96±7.00 (range 3.3-60) and diameter 23.58±7.84mm (10-40mm). Granulomas were present in 53 lymph nodes with mean SUV 8.82±4.83 (range 3.4-25) and diameter 21.44±18.30mm (10-35mm). Benign lymph nodes had a mean SUV 6.13±3.20 (range 1.7-15.4), and diameter 15.53±6.69mm (5-30mm). Although the comparison of suv and diameters have yielded significant difference with p<0.001 for both, the presence of considerable variability and overlap of values underscores the impact of EBUS-TBNA in differential diagnosis of mediastinal pathology.
- 15 September 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 52 (suppl 62) , PA2773
Comparison of endobronchial ultrasound-guided transbronchial needle aspiration and positron emission tomography standard uptake values in mediastinal or hilar lymph node evaluation in benign, granulomatous and malignant disease
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and positron emission tomography (PET) standard uptake values (SUV) are useful methods for evaluating mediastinal lymph node pathology. The aim this study was to compare EBUS TBNA and PET suv results in benign, granulomatous and malignant disease. The files of 151 patients who had FDG-PET scanning and underwent EBUS-TBNA between 2015-2017 were reviewed. The diagnoses were confirmed by needle aspiration cytology, histopathology and clinical follow-up. Malignant diseases included lung cancers, metastasis and lymphomas. Granulomatous diseases were mainly sarcoidosis and tuberculosis. Benign group comprised mainly of patients suspected with relapse of malignancy in whom it was disproved or no specific diagnosis was reached during follow-up. The patients included 101 males and 50 females with mean age 58.64±12.46 (26-86). A total of 356 stations were sampled with an average of 2.36 stations per case. Malignancy was observed in 100 lymph nodes with a mean SUV of 10.96±7.00 (range 3.3-60) and diameter 23.58±7.84mm (10-40mm). Granulomas were present in 53 lymph nodes with mean SUV 8.82±4.83 (range 3.4-25) and diameter 21.44±18.30mm (10-35mm). Benign lymph nodes had a mean SUV 6.13±3.20 (range 1.7-15.4), and diameter 15.53±6.69mm (5-30mm). Although the comparison of suv and diameters have yielded significant difference with p<0.001 for both, the presence of considerable variability and overlap of values underscores the impact of EBUS-TBNA in differential diagnosis of mediastinal pathology.
- 15 September 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 52 (suppl 62) , PA4331
Apelin and ischemia modified albumin levels in heart failure patients with sleep disordered breathing
Apelin is an adipocytokine produced in cardiomyocytes, vascular smooth muscle cells and endothelium, with an important role in the regulation of vascular tone and fluid balance. Plasma apelin levels are reduced in patients with heart failure. Ischemia modified albumin (IMA) production is stimulated by hypoxia and increases rapidly following myocardial ischemia. We aimed to assess the role of IMA and apelin in the pathogenesis of SDB related with heart failure. Consecutive 50 patients with heart failure were prospectively evaluated with full night polysomnography for the presence of SDB between April 2016 and May 2017. Cases diagnosed with SDB subsequently underwent BPAP titration. Apelin 13 and IMA levels were measured at baseline, following BPAP titration and after 3 months of BPAP therapy. SDB was detected in 48 of 50 patients (96%) with heart failure. Baseline apelin level was 8.635±6.344pg/ml and 16.353±11.999pg/ml on the morning of BPAP titration (p=0.022). IMA level was 4.511±2.026 IU/ml at baseline and 3.977±1.985 IU/ml on the morning of BPAP titration (p=0.302). Both baseline apelin and IMA levels were inversely correlated with apnea hypopnea index (r= -0.332, p=0.03) for apelin and (r= -0.399, p=0.009) for IMA. Apelin and IMA were assessed after 3 months of BPAP treatment but there was no significant difference with respect to baseline. Plasma apelin level increased after single night PAP treatment but the effect did not carry over after prolonged treatment which may be due to the multifactorial nature of heart failure or disease progression. IMA was not associated with PAP treatment.
- 15 September 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 52 (suppl 62) , PA4331
Apelin and ischemia modified albumin levels in heart failure patients with sleep disordered breathing
Apelin is an adipocytokine produced in cardiomyocytes, vascular smooth muscle cells and endothelium, with an important role in the regulation of vascular tone and fluid balance. Plasma apelin levels are reduced in patients with heart failure. Ischemia modified albumin (IMA) production is stimulated by hypoxia and increases rapidly following myocardial ischemia. We aimed to assess the role of IMA and apelin in the pathogenesis of SDB related with heart failure. Consecutive 50 patients with heart failure were prospectively evaluated with full night polysomnography for the presence of SDB between April 2016 and May 2017. Cases diagnosed with SDB subsequently underwent BPAP titration. Apelin 13 and IMA levels were measured at baseline, following BPAP titration and after 3 months of BPAP therapy. SDB was detected in 48 of 50 patients (96%) with heart failure. Baseline apelin level was 8.635±6.344pg/ml and 16.353±11.999pg/ml on the morning of BPAP titration (p=0.022). IMA level was 4.511±2.026 IU/ml at baseline and 3.977±1.985 IU/ml on the morning of BPAP titration (p=0.302). Both baseline apelin and IMA levels were inversely correlated with apnea hypopnea index (r= -0.332, p=0.03) for apelin and (r= -0.399, p=0.009) for IMA. Apelin and IMA were assessed after 3 months of BPAP treatment but there was no significant difference with respect to baseline. Plasma apelin level increased after single night PAP treatment but the effect did not carry over after prolonged treatment which may be due to the multifactorial nature of heart failure or disease progression. IMA was not associated with PAP treatment.
- Open Access
- 1 January 2018
- Published by Medknow in Nigerian Journal of Clinical Practice
- Vol. 21 (1) , 59-62
Vascular endothelial growth factor in pleural effusions and correlation with radiologic and biochemical parameters
Properties. Materials and Methods: The study included patients with pleural effusion. VEGF levels in the pleural fluid were measured by enzyme-linked immunosorbent assay. Results: A total of 97 patients who had exudative pleural effusion related to lung cancer (n = 17), nonpulmonary malignancies (n = 25), mesothelioma (n = 9), pneumonia (n = 14), tuberculosis (n = 8), miscellaneous causes (n = 6), and transudative effusion (n = 18) were included. Pleural VEGF levels were higher in exudative effusions with respect to transudative effusions (P < 0.001) and in effusions related to malignancies versus benign causes (P < 0.001). Pleural VEGF was inversely correlated with pleural fluid glucose and pH levels and had positive correlation with lactate dehydrogenase, protein levels (P < 0.001), hematocrit, and eosinophil values in the pleura (P < 0.05). Pleural VEGF levels were also higher in patients with massive effusions and pleural thickening (both P < 0.001). Conclusions: The overlap of pleural VEGF levels between the groups may limit the value of VEGF in discriminating between malignant versus benign and exudative versus transudative effusions; however, it may be a useful adjunct to various methods. The VEGF levels in pleural fluid seem to be related to the degree of inflammation and pleural invasion....
- 1 January 2018
- Published by Medknow in Nigerian Journal of Clinical Practice
- Vol. 21 (1) , 59-62
Open AccessVascular endothelial growth factor in pleural effusions and correlation with radiologic and biochemical parameters
Properties. Materials and Methods: The study included patients with pleural effusion. VEGF levels in the pleural fluid were measured by enzyme-linked immunosorbent assay. Results: A total of 97 patients who had exudative pleural effusion related to lung cancer (n = 17), nonpulmonary malignancies (n = 25), mesothelioma (n = 9), pneumonia (n = 14), tuberculosis (n = 8), miscellaneous causes (n = 6), and transudative effusion (n = 18) were included. Pleural VEGF levels were higher in exudative effusions with respect to transudative effusions (P < 0.001) and in effusions related to malignancies versus benign causes (P < 0.001). Pleural VEGF was inversely correlated with pleural fluid glucose and pH levels and had positive correlation with lactate dehydrogenase, protein levels (P < 0.001), hematocrit, and eosinophil values in the pleura (P < 0.05). Pleural VEGF levels were also higher in patients with massive effusions and pleural thickening (both P < 0.001). Conclusions: The overlap of pleural VEGF levels between the groups may limit the value of VEGF in discriminating between malignant versus benign and exudative versus transudative effusions; however, it may be a useful adjunct to various methods. The VEGF levels in pleural fluid seem to be related to the degree of inflammation and pleural invasion....
- 19 December 2016
- Published by Springer Nature in Sleep and Breathing
- Vol. 21 (2) , 475-478
Obstructive sleep apnea is the triggering factor for massive hemoptysis
Purpose The purpose of this study was to investigate the prevalence of obstructive sleep apnea (OSA) in patients with hemoptysis. Methods Files of patients who had undergone bronchial arterial embolization due to hemoptysis between 1 December 2009 and 2015 were evaluated and interviews of patients were conducted until 1 June 2016. Pittsburgh Sleep Quality Index (PSQI), STOP and STOP-BANG surveys were administered. OSA risk was determined with Berlin Questionnaire. Results Study group consisted of 53 patients and 58 control subjects. Mean age was 46.94 ± 14.36 and 41.97 ± 12.92 in patient and control group, respectively. Of these patients, seven had re-embolization procedure because of recurrence of hemoptysis. High OSA risk was more common among patients with hemoptysis (24.5%, n = 13) than the control group (8.6%, n = 5) (p = 0.023). Percentage of high risk OSA patients with massive hemoptysis, nonmassive hemoptysis, and control subjects was 29.7% (n = 11), 12.5% (n = 2), and 8.6% (n = 5), respectively (p = 0.022). There were more high OSA risk subjects among patients with idiopathic hemoptysis 44.4% (four out of nine), while 20.5% (nine out of 53) patients with a known etiology had high risk (p = 0.127). The number of patients with high OSA risk was also higher in patients who required a second embolization procedure (four out of seven, 57.1%), while 19.6% of patients without need for re-embolization had high risk (p = 0.031). Conclusions OSA is found to be a risk factor for hemoptysis and also may provoke massive hemoptysis. It seems reasonable to consider OSA as an underlying condition in idiopathic hemoptysis. OSA may contribute to embolization failure.
- 19 December 2016
- Published by Springer Nature in Sleep and Breathing
- Vol. 21 (2) , 475-478
Obstructive sleep apnea is the triggering factor for massive hemoptysis
Purpose The purpose of this study was to investigate the prevalence of obstructive sleep apnea (OSA) in patients with hemoptysis. Methods Files of patients who had undergone bronchial arterial embolization due to hemoptysis between 1 December 2009 and 2015 were evaluated and interviews of patients were conducted until 1 June 2016. Pittsburgh Sleep Quality Index (PSQI), STOP and STOP-BANG surveys were administered. OSA risk was determined with Berlin Questionnaire. Results Study group consisted of 53 patients and 58 control subjects. Mean age was 46.94 ± 14.36 and 41.97 ± 12.92 in patient and control group, respectively. Of these patients, seven had re-embolization procedure because of recurrence of hemoptysis. High OSA risk was more common among patients with hemoptysis (24.5%, n = 13) than the control group (8.6%, n = 5) (p = 0.023). Percentage of high risk OSA patients with massive hemoptysis, nonmassive hemoptysis, and control subjects was 29.7% (n = 11), 12.5% (n = 2), and 8.6% (n = 5), respectively (p = 0.022). There were more high OSA risk subjects among patients with idiopathic hemoptysis 44.4% (four out of nine), while 20.5% (nine out of 53) patients with a known etiology had high risk (p = 0.127). The number of patients with high OSA risk was also higher in patients who required a second embolization procedure (four out of seven, 57.1%), while 19.6% of patients without need for re-embolization had high risk (p = 0.031). Conclusions OSA is found to be a risk factor for hemoptysis and also may provoke massive hemoptysis. It seems reasonable to consider OSA as an underlying condition in idiopathic hemoptysis. OSA may contribute to embolization failure.
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 223, 212-214
An unusual cause of pulmonary hypertension: Swyer–James–Macleod syndrome
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 223, 212-214
An unusual cause of pulmonary hypertension: Swyer–James–Macleod syndrome